

## Sinclair Pharma plc ("Sinclair" or "the Company")

### Result of General Meeting

**10 December 2009, Godalming, UK:** Sinclair Pharma plc (the "Company" or "Sinclair": SPH:L), the international specialty pharma company, is pleased to announce that at a General Meeting of the Company held earlier today the resolution, set out in the notice of general meeting annexed to the prospectus to shareholders dated 24 November 2009, was duly passed. The results of the proxy votes lodged in advance of the General Meeting will be available on Sinclair's website shortly.

In accordance with Sinclair's obligations under Listing Rule 9.6.2, two copies of the resolutions passed as special business at the General Meeting have been submitted to the UK Listing Authority and will shortly be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25, The North Colonnade, Canary Wharf, London, E14 5HS.

#### For further information please contact:

**Sinclair Pharma plc**  
Dr Michael Flynn, CEO  
Alan Olby, Company Secretary

Tel: +44 (0) 1483 410 600

**Singer Capital Markets Ltd**  
Shaun Dobson  
Claes Spång

Tel: +44 (0)20 3205 7500

**Capital MS&L**  
Mary Clark  
Anna Mitchell

Tel +44 (0)20 7307 5340

#### Notes to Editors:

#### About Sinclair Pharma Plc [www.sinclairpharma.com](http://www.sinclairpharma.com)

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat dermatological, oral care and gynaecological diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is already present in France, Italy, and Spain, and a complementary marketing partner network that spans more than 90 countries.

*"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.*